Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing Colorectal Cancer Awareness Month by highlighting the ...

BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study in collaboration with The University of Texas MD Anderson Cancer Center, ...

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...

Molecular mechanism in urothelial carcinoma with FGFR3 mutation.

This is a preview. Log in through your library . Abstract The molecular mechanism of plant polyploid stress resistance has been a hot topic in biological research. In this study, Populus diploids and ...

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences ...